BA
HRMY icon

Bridgewater Associates’s Harmony Biosciences HRMY Stock Holding History

Bridgewater Associates’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.05M Sell
248,575
-2,931
-1% -$92.5K 0.04% 353
2026
Q1 		$7.04M Buy
251,506
+22,992
+10% +$754K 0.03% 340
2025
Q4 		$8.55M Buy
228,514
+16,988
+8% +$559K 0.03% 398
2025
Q3 		$5.83M Buy
+211,526
New +$7.29M 0.02% 457

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgewater Associates's HRMY Position: Q2 2026 in Review

Bridgewater Associates reduced its Harmony Biosciences (HRMY) stake by 1.2% in Q2 2026, selling an estimated $92.5K and leaving 248,575 shares worth $9.05M. The position accounts for 0.04% of the portfolio, ranked #353.

Bridgewater Associates first reported a position in HRMY in Q3 2025 and has held it in 4 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Bridgewater Associates held 248,575 shares of Harmony Biosciences worth $9.05M as of Q2 2026.
  • Bridgewater Associates sold 2,931 Harmony Biosciences shares in Q2 2026, an estimated $92.5K.
  • Harmony Biosciences made up 0.04% of Bridgewater Associates's portfolio in Q2 2026, its #353 holding.
  • Bridgewater Associates first reported a position in Harmony Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.